• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    3/6/24 4:31:05 PM ET
    $ARTL
    $ATRA
    $AVTX
    $BEAT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARTL alert in real time by email

    Gainers

    • SCWorx (NASDAQ:WORX) stock increased by 60.8% to $2.75 during Wednesday's after-market session. The market value of their outstanding shares is at $3.3 million.
    • IO Biotech (NASDAQ:IOBT) stock increased by 11.44% to $1.85. The company's market cap stands at $121.8 million. As per the press release, Q4 earnings came out yesterday.
    • Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 8.11% to $1.6. The market value of their outstanding shares is at $5.1 million.
    • NextCure (NASDAQ:NXTC) shares increased by 8.01% to $1.82. The market value of their outstanding shares is at $50.7 million.
    • Atara Biotherapeutics (NASDAQ:ATRA) shares moved upwards by 7.47% to $0.75. The market value of their outstanding shares is at $76.4 million.
    • Telesis Bio (NASDAQ:TBIO) stock moved upwards by 4.99% to $0.51. The market value of their outstanding shares is at $15.4 million.

    Losers

    • Nexalin Technology (NASDAQ:NXL) shares fell 14.4% to $0.45 during Wednesday's after-market session. The market value of their outstanding shares is at $3.2 million.
    • Avalo Therapeutics (NASDAQ:AVTX) shares decreased by 12.04% to $4.53. The market value of their outstanding shares is at $3.6 million.
    • HeartBeam (NASDAQ:BEAT) shares declined by 11.97% to $1.43. The market value of their outstanding shares is at $37.5 million.
    • Trxade Health (NASDAQ:MEDS) shares declined by 10.7% to $15.45. The market value of their outstanding shares is at $18.6 million.
    • Vicarious Surgical (NYSE:RBOT) stock declined by 9.34% to $0.31. The market value of their outstanding shares is at $54.7 million. As per the news, the Q4 earnings report came out 2 days ago.
    • Creative Medical Tech (NASDAQ:CELZ) stock fell 8.62% to $4.35. The market value of their outstanding shares is at $6.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARTL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARTL
    $ATRA
    $AVTX
    $BEAT

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    4/9/2026$48.00Outperform
    Wolfe Research
    Avalo Therapeutics Inc.
    $AVTX
    4/6/2026$52.00Mkt Outperform
    Citizens
    Heartbeam Inc.
    $BEAT
    3/31/2026$4.00Buy
    B. Riley Securities
    Heartbeam Inc.
    $BEAT
    3/27/2026$5.00Buy
    D. Boral Capital
    Heartbeam Inc.
    $BEAT
    3/16/2026$8.00Buy → Speculative Buy
    The Benchmark Company
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    IO Biotech Inc.
    $IOBT
    1/26/2026$0.50Overweight → Neutral
    Piper Sandler
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $ARTL
    $ATRA
    $AVTX
    $BEAT
    SEC Filings

    View All

    SEC Form 424B5 filed by Heartbeam Inc.

    424B5 - HeartBeam, Inc. (0001779372) (Filer)

    4/14/26 4:22:46 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SCWorx Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - SCWorx Corp. (0001674227) (Filer)

    4/10/26 5:15:07 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form DEFA14A filed by Avalo Therapeutics Inc.

    DEFA14A - Avalo Therapeutics, Inc. (0001534120) (Filer)

    4/10/26 4:02:49 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $ATRA
    $AVTX
    $BEAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Panacea Innovation Ltd bought $670,422 worth of shares (55,000 units at $12.19) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    8/19/25 8:15:04 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Panacea Innovation Ltd bought $186,372 worth of shares (19,335 units at $9.64) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    7/21/25 9:00:05 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Hunter Heidi bought $20,884 worth of shares (15,000 units at $1.39) (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/2/25 7:53:36 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $ATRA
    $AVTX
    $BEAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/8/26 4:51:43 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sullivan Christopher Ryan

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/3/26 3:14:43 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/3/26 3:13:22 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $ATRA
    $AVTX
    $BEAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HeartBeam Announces Pricing of $10 Million Public Offering of Common Stock

    Offering is being led by HeartBeam's first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock for total gross proceeds of $10 million, before deducting underwriting discounts, commissions, and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares to cover over-allotments, if any, at the public offering price, le

    4/14/26 10:00:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Announces Proposed Public Offering of Common Stock

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). All of the securities to be sold in the proposed offering will be offered by HeartBeam. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The Company intends to use the net proceeds from this offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system,

    4/14/26 4:05:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21

    ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)). The exclusive event will feature Nexalin's CEO Mark White, who will provide an in-depth overview of the company's differentiated approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will highlight Nexalin's expanding body of clinical evidence—including peer-reviewed studies and collaborations with leading institutions such as UC San Diego—while outlining progress across its next-generation product portfolio, including the Gen-3 H

    4/14/26 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ARTL
    $ATRA
    $AVTX
    $BEAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Avalo Therapeutics with a new price target

    Wolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00

    4/9/26 8:40:45 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens initiated coverage on Avalo Therapeutics with a new price target

    Citizens initiated coverage of Avalo Therapeutics with a rating of Mkt Outperform and set a new price target of $52.00

    4/6/26 8:44:25 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on HeartBeam with a new price target

    B. Riley Securities initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00

    3/31/26 8:12:24 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $ARTL
    $ATRA
    $AVTX
    $BEAT
    Leadership Updates

    Live Leadership Updates

    View All

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

    SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025. Mr. Spring had been serving as a financial consultant to the Company since December 2024. The appointment strengthens Artelo's financial leadership as it advances its clinical pipeline and corporate growth initiatives. Mark Spring brings 30 years of experience in life sciences to his role, including f

    10/27/25 8:00:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    $ATRA
    $AVTX
    $BEAT
    Financials

    Live finance-specific insights

    View All

    Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21

    ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)). The exclusive event will feature Nexalin's CEO Mark White, who will provide an in-depth overview of the company's differentiated approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will highlight Nexalin's expanding body of clinical evidence—including peer-reviewed studies and collaborations with leading institutions such as UC San Diego—while outlining progress across its next-generation product portfolio, including the Gen-3 H

    4/14/26 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    HeartBeam Reports Fourth Quarter and Full Year 2025 Results

    HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial Partner ClearCardio™ to Bring HeartBeam's 3D ECG Technology to High-Growth Preventive Cardiology Market First Patients Enrolled in Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Completed the First Working Prototype of an Extended-Wear 12-Lead ECG Patch Strategic Collaboration with the Icahn School of Medicine at Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. ET   HeartBeam, Inc. (NASDAQ:BEAT), a

    3/12/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2025, and will be providing updates on its key strategic growth initiatives, specifically the limited commercial launch and significant developments on the 12-lead ECG extended wear patch. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. They will

    3/4/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $ARTL
    $ATRA
    $AVTX
    $BEAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by NextCure Inc.

    SC 13G/A - NextCure, Inc. (0001661059) (Subject)

    11/14/24 6:59:21 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care